Arteaga-Gómez AC, Castellanos- Barroso G, Colin-Valenzuela A, García-Vargas J, Márquez-Acosta G, Reyes-Muñoz E

Language: Spanish
References: 12
Page: 11-17
PDF size: 504.79 Kb.

ABSTRACT

Background: The increase of endometrial cancer survivors’ incidence let the question if the management of postmenopausal hormone therapy will increase the risk of carcinogenesis.
Objective: To determine the recurrence rate, in postmenopausal patients managed with hormonal therapy (HT) compared with patients without HT treated in El Instituto Nacional de Perinatología Isidro Espinosa de los Reyes.
Patients and method: Retrospective, analytical, historical cohort. We analyzed 29 patients who met the inclusion criteria from January 1, 2000 to December 31, 2008
Results: The average age for diagnosis of endometrial cancer was 45 years. 100% of the patients had surgical treatment (82.8% routine endometrial open approach, laparoscopic 17.2%). The 93% of patients had criteria to begin HT, however, was administered alone to 37% due to medical criteria, 36% received tibolona, 64% received estrogen with an average administration time of 39 and 54 months for each one without affecting disease-free period. Patients who received hormonal therapy had no recurrence of disease-free period of 58 months. There was only one patient with recurrence for which no hormonal therapy was administered.
Conclusions: Patients who were under hormonal therapy did not modify the rate of endometrial cancer recurrence compared with those without HT. Although we cannot conclude irrefutably the safety of hormone therapy, based on biological knowledge and the results of this study, hormone therapy can be safely administered in stage l and ll.

REFERENCES

1. Sorosky J. Endometrial cancer. Clinical Expert Series. Obstet Gynecol 2008;111:436-447.

2. Dirección General de Estadística, Secretaria de Salud. Compendio del Registro Histopatológico de Neoplasias. México, DGE-SSA, 2003.

3. Jemal A, Siegel R, Ward E, Hao Y, et al. Cancer Statistics 2009. CA Cancer J Clin 2009;59(4):225-249.

4. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. American College of Obstetricians and Gynecologists. Obstet Gynecol 2005;106:413-425.

5. Barakat RR, Lev G, Hummer AJ, Sonoda Y, et al. Twelveyear experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gyncol Oncol 2007;105:150-156.

6. DiSaia PJ, Creasman WT. Clinical gynaecologic oncology. Adenocarcinoma of the uterus, Chapter 5. 7th ed. Philadelphia: Mosby, 2007.

7. Grady D, Gebrestsadik T, Kerlikowske K, Ernstr V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.

8. Byrant GW. Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990;83:725-726.

9. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-191.

10. Suriano KA, McHale M, McLaren CE, Li KT, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555-560.

11. Ayhan A, Taskiran C, Simsek S, Sever A. Does immediate hormone replacement therapy affects the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 2006;16:805-808.

12. Courneya KS, Karvinen KH, Campbell KL, Pearcey RG, et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol 2005;97:422-430.